Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lobeglitazone on Pharmacokinetics of Sitagliptin in Healthy Male Volunteers
NCT02827890Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve over the dosing interval at Day 5 and Maximum Steady State Plasma Concentration at Day 5. Started Apr 2016; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02827890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02827890.